MetaCap

MiMedx Group (MDXG) vs Avita Medical (RCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avita Medical (RCEL) has outperformed MiMedx Group (MDXG) over the past year, gaining 312.1% versus a loss of 54.9%. Over five years, RCEL leads with a +10.8% price change compared with -58.6% for MDXG. Avita Medical is the larger company by market cap ($495.0 million vs $445.1 million), about 1.1 times the size, while MiMedx Group is growing revenue faster (+20.0% vs +11.5%).

MiMedx Group converts more of its revenue into profit, with a net margin of 11.6% versus -67.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MDXG-54.88%RCEL+312.14%
+387%+155%-76%
Nov 21, 20251 yearNov 20, 2026
MDXG-60.54%RCEL+4.20%
+44%-19%-83%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MDXG versus RCEL key metrics
MetricMDXGRCEL
Share price$3.05$15.62
Market cap$445.07M$494.96M
1-day change-1.93%-2.31%
YTD return-54.95%+352.75%
1-year return-54.88%+312.14%
5-year return-58.62%+10.78%
Forward P/E122.00—
EPS (TTM)$-0.13$-1.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$418.63M$71.61M
Revenue growth (YoY)+19.99%+11.45%
Net income (latest FY)$48.58M$-48.59M
Gross margin82.56%82.13%
Operating margin15.26%-59.40%
Net margin11.60%-67.85%
52-week high$7.45$18.43
52-week low$3.03$3.22
Distance from 52-week high-59.06%-15.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+129.51%+32.46%
Average volume1.39M417.02K
Shares outstanding145.93M31.69M
Employees808226
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RCEL has outperformed MDXG by 367.0 percentage points over the past year.
  • MiMedx Group is more profitable, keeping 11.6 cents of every revenue dollar as net income versus -67.8 cents for Avita Medical.
  • MiMedx Group grew revenue faster in its latest fiscal year (+19.99% vs +11.45%).

About MiMedx Group

MDXG stock →

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.

Health Care · Medical/Dental Instruments · 808 employees

About Avita Medical

RCEL stock →

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.

Health Care · Medical/Dental Instruments · 226 employees

MDXG vs RCEL FAQ

Which is bigger, MiMedx Group or Avita Medical?

Avita Medical (RCEL) is larger, with a market capitalization of $494.96M compared with $445.07M for MiMedx Group (MDXG).

Which stock has performed better over the past year, MDXG or RCEL?

RCEL returned +312.14% over the past 12 months, compared with -54.88% for MDXG (price return, excluding dividends). Past performance does not predict future results.

Are MiMedx Group and Avita Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons